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The evolution of hubs
 
etabolic networks rely heavily on a few crucial metabolic hubs, such as ATP,
NADH, and glutamate, that are widely used in many cellular biochemical
reactions. In contrast to hubs, most other metabolites each participate in only
a few reactions. Now, research from Thomas Pfeiffer, Orkun Soyer, and Sebastian
Bonhoeffer (ETH Zürich, Switzerland) shows that hubs are the natural byproduct of a
widely accepted scenario of network evolution.
The scenario, originally proposed by Kacser and Beeby, suggests that a few multi-
functional enzymes evolved to create a large network of highly specialized enzymes. In
the new work, the Swiss group ran computer simulations of this scenario using a small
theoretical network initially consisting of 128 metabolites, one metabolite transporter, and
seven catalytic enzymes. These constituents evolved via small mutations or duplications
that improved projected growth rates.
The simulations revealed that networks optimized for growth rates acquired hubs. Some
scientists have theorized that hubs evolved in part to improve a network’s ability to withstand
perturbations (i.e., the mutational loss of a metabolite). The new simulations suggest, however,
that growth rate alone exerts enough selective pressure. Hub frequency varied somewhat from
that found in the entire 
 
E. coli
 
 metabolic network. But if the authors compared their simulations
to smaller natural subnetworks, such as glycolysis, then the hub distributions matched closely.
Natural hubs are especially important in the transfer of biochemical groups (e.g.,
phosphate or amino acids) between metabolites. According to the new findings, these
group transfer reactions are important for the emergence of hubs. When the simulations
were run in their absence—groups were added or taken away, but not transferred—
hubs were much less prominent.
“Metabolites are hubs because they are key in transfer reactions,” says Pfeiffer. “One
metabolite evolves such that it’s the best donor for a particular group. The rest of the network
benefits by maintaining that donor at a high concentration. And all reactions that require that
specific group should specialize to rely on this donor, because it’s the best donor around.” 
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Highly connected hubs are common in a 
simulated network (top), as in natural net-
works (middle), but rare if group transfer 
reactions are excluded (bottom).
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DNA damage lures T cells
 
ew research from Stephan Gasser,
David Raulet (University of
California, Berkeley, CA), and
colleagues suggests that immune cells recog-
nize tumors based on their damaged DNA.
Immune cells have been shown to
kill certain tumor cells. Unlike pathogens,
however, cancer cells lack the tags that
mark them as foreign and thus possibly
dangerous. “What property of a tumor
could the innate immune system recog-
nize?” Raulet wondered. “Most things
cancer cells do, normal cells do too.”
Raulet and colleagues turned to the
DNA damage response pathway. “This is
a basic cell process,” he says, “that recent
evidence suggests is triggered in cancer
cells.” The DNA damage response is
known for inducing cell cycle arrest and,
if the damage is extensive, apoptosis.
Now, the group shows that the pathway
also induces activators of immune cells.
In nontumor cells, damaging agents
N
 
that cause DNA breaks
or stalled replication
forks induced ligands
that are known to be
recognized by the im-
mune cell receptor
NKG2D, which is found
on T cells and natural
killer cells. A tumor cell line expressed
NKG2D ligands constitutively. In both
cases, ligand expression required the
damage recognition kinases, ATM and
ATR, and downstream kinase Chk1.
The NKG2D ligands made cells
more sensitive to killing by natural killer
cells in vitro. The authors earlier reported
that transfecting NKG2D ligands into
tumor cells that lack them leads to tumor
rejection and recently found that blocking
NKG2D reduced tumor rejection. The
group has now created mice lacking
NKG2D to examine its effects on natural
tumorigenesis. Other immune receptors
might also be involved, but, as their
ligands are not characterized, it will take
time to examine all the possibilities.
The efficacy of the damage response
in preventing cancer progression is not
known, but the findings suggest that part
of the success of chemotherapy and radio-
therapy might be due to the increased
expression of ligands that activate immune
cells. Perhaps combining chemotherapy
with infusions of immune cells might
have a much greater effect than does ei-
ther separately. 
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DNA damage (red) turns on NKG2D ligands (left) that make the cells 
more sensitive to killing by T cells (right).
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